Can the well-credentialed neuroblastoma tumor antigen GD2 be exploited for T-cell-based immunotherapy of pediatric sarcomas?
S. Ramakrishna
No relevant relationships to disclose
S. Gottschalk
No relevant relationships to disclose
R. Morgan
No relevant relationships to disclose
G. Dotti
No relevant relationships to disclose
M. K. Brenner
No relevant relationships to disclose
R. Orentas
No relevant relationships to disclose
C. Mackall
No relevant relationships to disclose